Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
-
Compare toBuphenyl®*
Inactive Ingredients
Calcium stearate, NF and Colloidal silicon dioxide, NF
*Buphenyl® is a registered trademark of Horizon Pharma, Inc.
Sodium Phenylbutyrate Powder (250 grams)
-
Package size3 g/Tsp
-
Strength250 g
-
NDC Code42794-0086-14